Tuesday, December 3, 2024

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Stryker Corp. (SYK) and Lam Research Corp. (LRCX), as well as a micro-cap stock, ImmuCell Corp. (ICCC). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Amazon’s shares have outperformed the Zacks Internet – Commerce industry over the past year (+45.5% vs. +40.8%). The Zacks analyst believes that strengthening AWS services portfolio and its growing adoption rate have contributed well to the stock's performance. Ultrafast delivery services, expanding content portfolio and Amazon’s expanding global presence have also benefited the company. Deepening focus on generative AI is a major plus.

However, macroeconomic challenges remain headwinds. Rising transportation and fulfillment center costs are concerns.

(You can read the full research report on Amazon here >>>)

Stryker’s shares have outperformed the Zacks Medical - Products industry over the past year (+33.9% vs. +20.9%). The Zacks analyst believes that strong international sales, ongoing procedural recovery and a strong order book for capital equipment bode well for the company. Strong customer demand is a major plus.

Yet, inflationary pressure and supply-chain challenges continue to plague Stryker. Stiff competition in the MedTech space remains a headwind.

(You can read the full research report on Stryker here >>>)

Shares of Lam Research have underperformed the Zacks  Electronics – Semiconductors industry over the past year (+10.6% vs. +45.7%). Per the Zacks analyst, global spending on mature nodes is likely to be flat year over year. Growing tensions between the United States and China remain major concerns and have contributed to the stocks underperformance this year.

However, the company is riding on its strength across 3D DRAM and advanced packaging technologies. Also, rebound in the system business owing to improving memory spending is a positive.

(You can read the full research report on Lam Research here >>>)

Immucell’s shares have underperformed the Zacks Medical - Products industry over the last six months (-3.9% vs. +11.9%). The Zacks analyst believes that the company has been hindered by high production costs and increased depreciation from expanded facilities. High customer concentration, shareholder dilution and competition from giants like Zoetis and Merck also pose risks.

Yet, robust customer demand for First Defense has been a key driver of sales growth. The remediation of contamination issues and investments in capacity expansion have positioned the company to stabilize output at higher levels.

(You can read the full research report on Immucell here >>>)

Other noteworthy reports we are featuring today include Duke Energy Corp. (DUK), Aon plc (AON) and HCA Healthcare, Inc. (HCA).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>